Docoh
Loading...

TYME Tyme

Filed: 8 Nov 21, 6:31am

Table of Contents

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended:

September 30, 2021

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                     to                     

Commission File Number: 001-38169

 

TYME TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

45-3864597

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

1 Pluckemin Way – Suite 103

Bedminster, New Jersey 07921

(Address of principal executive offices)

(Zip Code)

(212) 461-2315

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value

TYME

Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

Non-accelerated filer

 

 

Smaller reporting company

 

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

The number of shares outstanding of the registrant’s common stock on November 3, 2021 was 172,206,894.


Table of Contents

TABLE OF CONTENTS

 

 

 

 

 

Page

 

 

 

Special Note Regarding Forward-Looking Statements

 

1

 

 

 

 

 

General

 

2

 

 

 

 

 

 

 

PART I- FINANCIAL INFORMATION

 

 

Item 1.

 

Financial Statements.

 

3

 

 

 

 

 

 

 

Condensed Consolidated Balance Sheets as of September 30, 2021 (unaudited) and March 31, 2021.

 

3

 

 

 

 

 

 

 

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) for the three and six months ended September 30, 2021 and 2020.

 

4

 

 

 

 

 

 

 

Condensed Consolidated Statements of Stockholders’ Equity (unaudited) for the three and six months ended September 30, 2021 and 2020.

 

5

 

 

 

 

 

 

 

Condensed Consolidated Statements of Cash Flows (unaudited) for the six months ended September 30, 2021 and 2020.

 

6

 

 

 

 

 

 

 

Notes to Unaudited Condensed Consolidated Financial Statements.

 

7

 

 

 

 

 

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

20

 

 

 

 

 

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk.

 

30

 

 

 

 

 

Item 4.

 

Controls and Procedures.

 

30

 

 

 

 

 

 

 

PART II- OTHER INFORMATION

 

 

 

 

 

 

 

Item 1.

 

Legal Proceedings.

 

31

 

 

 

 

 

Item 1A.

 

Risk Factors.

 

31

 

 

 

 

 

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds.

 

31

 

 

 

 

 

Item 3.

 

Defaults Upon Senior Securities.

 

31

 

 

 

 

 

Item 4.

 

Mine Safety Disclosures.

 

31

 

 

 

 

 

Item 5.

 

Other Information.

 

31

 

 

 

 

 

Item 6.

 

Exhibits.

 

32

 

 

 

 

 

SIGNATURES

 

 

 

33

 

 

 


Table of Contents

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS


Certain statements in this Quarterly Report on Form 10-Q are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. All statements contained in this Quarterly Report on Form 10-Q other than statements of historical facts, including statements regarding our future results of operations and financial position, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements within this report include, without limitation, statements regarding our drug candidates and technologies (including SM-88 and TYME- 18) and their clinical potential and non-toxic safety profiles, our drug development plans and strategies, ongoing and planned preclinical or clinical trials, preliminary data results and the therapeutic design and mechanisms of our drug candidates. The words “believes,” “expects,” “hopes,” “may,” “will,” “plan,” “intends,” “estimates,” “could,” “should,” “would,” “continue,” “seeks,” “anticipates,” and similar expressions (including their use in the negative) are intended to identify forward-looking statements. Forward-looking statements can also be identified by discussions of future matters such as: the effect of the COVID-19 pandemic and the associated impact on the national and global economy as well as impacts on the Company's ongoing clinical trials and ability to analyze data from those trials; the cost of development and potential commercialization of our lead drug candidate and of other new product candidates; expected releases of interim or final data from our clinical trials; possible collaborations; the timing, scope, status, objectives of our ongoing and planned trials; the success of management transitions and strategic initiatives; and other statements that are not historical. The forward-looking statements contained in this report are based on management’s current expectations and projections which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include but are not limited to: the severity, duration, and economic impact of the COVID-19 pandemic; our ability to achieve the intended benefits of our strategic initiatives; that certain information is of a preliminary nature and may be subject to change; uncertainties inherent in the cost and outcomes of research and development, including the cost and availability of acceptable-quality clinical supply, and the ability to achieve adequate start and completion dates, as well as uncertainties in clinical trial design and patient enrollment, dropout or discontinuation rates; the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with early, initial data, including the risk that the final data from any clinical trials may differ from prior or preliminary study data or analyses and may not support further clinical development; and that past reported data are not necessarily predictive of future patient or clinical data outcomes; whether and when any applications or other submissions for SM-88 or other drug candidates may be filed with regulatory authorities; whether and when regulatory authorities may approve any applications or submissions; decisions by regulatory authorities regarding labeling and other matters that could affect commercial availability of SM-88 or other drug candidates; the ability of TYME and its collaborators to develop and realize collaborative synergies; competitive developments; and the factors described in the section captioned “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended March 31, 2021, filed with the U.S. Securities and Exchange Commission on June 10, 2021, as well as subsequent reports we file from time to time with the U.S. Securities and Exchange Commission (available at www.sec.gov).

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, achievements or events and circumstances reflected in the forward-looking statements will occur. Moreover, we operate in a competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from any forward-looking statements we make. We cannot assure you that forward-looking statements in this report or therein will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us to any other person that we will achieve our objectives and plans in any specified time frame, or at all. We disclaim any intent or duty to update any of these forward-looking statements after completion of this Quarterly Report on Form 10-Q to conform these statements to actual results or revised expectations.

The cautionary statements made in this report are intended to be applicable to all related forward-looking statements wherever they may appear in this report. We urge you not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except as required by law, we assume no obligation to update our forward-looking statements, even if new information becomes available in the future.

 

1


Table of Contents

GENERAL

Unless the context otherwise requires, all references in this Quarterly Report on Form 10-Q to the “Company,” “TYME,” “we,” “us” or “our” refer to Tyme Technologies, Inc., together with its subsidiaries.

Throughout this Quarterly Report on Form 10-Q, we have used terms which are defined below:  

AEs

Adverse events

KOLs

Key opinion leaders

ASC

Accounting Standards Codification

LLC

Limited Liability Company

ASU

Accounting Standards Update

MOA

Mechanism of Action

ATM

At-the-Market offering

MPS

Methoxsalen, phenytoin, and sirolimus

CBR

Clinical benefit rate

ORR

Objective response rate

CDK4/6

A gene that makes a protein involved in the cell cycle (the process a cell goes through each time it divides). Mutations (changes) in the CDK4/6 gene may cause cells to divide too quickly or in an uncontrolled way.

OS

Overall survival

CMBTs

Cancer metabolism-based therapies

PanCAN

Pancreatic Cancer Action Network

DOR

Duration of response

PFS

Progression free survival

EPS

Earnings Per Share

PI

Principal Investigator

FASB

Financial Accounting Standards Board

RECIST

Response Evaluation Criteria In Solid Tumors

FDA

Food and Drug Administration

ROU

Right-of-use

GAAP

Generally Accepted Accounting Principles

SAB

Staff Accounting Bulletin

HR+

hormone receptor positive

SEC

U.S. Securities and Exchange Commission

HER2-

Human epidermal growth factor receptor 2 negative

SPA

Securities Purchase Agreement

IP

Intellectual Property

 

 


 

2


Table of Contents

 

 

PART I – FINANCIAL INFORMATION

Item 1.

Financial Statements.

Tyme Technologies, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

 

 

 

September 30, 2021

 

 

March 31, 2021

 

 

 

(unaudited)

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

29,215,611

 

 

$

107,516,420

 

Marketable securities

 

 

46,294,783

 

 

 

 

Prepaid clinical costs

 

 

560,098

 

 

 

987,470

 

Prepaid expenses and other current assets

 

 

1,309,366

 

 

 

1,152,970

 

Total current assets

 

 

77,379,858

 

 

 

109,656,860

 

 

 

 

 

 

 

 

 

 

Prepaid clinical costs, net of current portion

 

 

 

 

 

530,989

 

Operating lease right-of-use asset

 

 

57,396

 

 

 

75,471

 

Marketable securities

 

 

20,369,388

 

 

 

 

Total assets

 

$

97,806,642

 

 

$

110,263,320

 

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable and other current liabilities (including $68,000 and

   $87,000 of related party accounts payable, respectively)

 

$

3,339,131

 

 

$

3,842,390

 

Severance payable

 

 

653,295

 

 

 

726,027

 

Accrued bonuses

 

 

741,197

 

 

 

1,040,710

 

Operating lease liability

 

 

38,883

 

 

 

34,658

 

Total current liabilities

 

 

4,772,506

 

 

 

5,643,785

 

Long-term liabilities

 

 

 

 

 

 

 

 

Severance payable, net of current portion

 

 

642,958

 

 

 

850,709

 

Operating lease liability, net of current portion

 

 

19,267

 

 

 

41,256

 

Warrant liability

 

 

862,612

 

 

 

1,931,921

 

Total liabilities

 

 

6,297,343

 

 

 

8,467,671

 

Commitments and contingencies (see Note 9)

 

 

 

 

 

 

 

 

Stockholders' equity

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 0

   shares issued and outstanding

 

 

 

 

 

 

Common stock, $0.0001 par value, 300,000,000 shares authorized,

172,206,894 issued and outstanding at September 30, 2021, 300,000,000 authorized, 172,200,644 issued and outstanding at March 31, 2021

 

 

17,223

 

 

 

17,222

 

Additional paid in capital

 

 

239,838,521

 

 

 

238,572,442

 

Accumulated other comprehensive loss

 

 

(58,557

)

 

 

 

Accumulated deficit

 

 

(148,287,888

)

 

 

(136,794,015

)

Total stockholders' equity

 

 

91,509,299

 

 

 

101,795,649

 

Total liabilities and stockholders' equity

 

$

97,806,642

 

 

$

110,263,320

 

 

 

The Notes to Condensed Consolidated Financial Statements are an integral part of these statements.

 

3


Table of Contents

Tyme Technologies, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

 

 

Three Months Ended

September 30,

 

 

Six Months Ended                   September 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Revenues

$

0

 

 

$

0

 

 

$

0

 

 

$

0

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

3,495,416

 

 

 

4,707,448

 

 

 

7,679,827

 

 

 

9,422,743

 

General and administrative (including $151,000, $138,000, $266,000 and $341,000 of related party legal expenses, respectively)

 

2,433,099

 

 

 

2,613,689

 

 

 

4,901,258

 

 

 

5,670,761

 

Total operating expenses

 

5,928,515

 

 

 

7,321,137

 

 

 

12,581,085

 

 

 

15,093,504

 

Loss from operations

 

(5,928,515

)

 

 

(7,321,137

)

 

 

(12,581,085

)

 

 

(15,093,504

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of warrant liability

 

344,166

 

 

 

489,572

 

 

 

1,069,309

 

 

 

(2,773,699

)

Gain on warrant exchange

 

 

 

 

 

 

 

 

 

 

2,228,697

 

Other income

 

39,007

 

 

 

7,011

 

 

 

58,530

 

 

 

17,513

 

Interest expense

 

(19,368

)

 

 

(25,980

)

 

 

(40,627

)

 

 

(55,356

)

Total other income (expense)

 

363,805

 

 

 

470,603

 

 

 

1,087,212

 

 

 

(582,845

)

Net loss

$

(5,564,710

)

 

$

(6,850,534

)

 

$

(11,493,873

)

 

$

(15,676,349

)

Basic and diluted loss per common share

$

(0.03

)

 

$

(0.05

)

 

$

(0.07

)

 

$

(0.12

)

Basic and diluted weighted average shares outstanding

 

172,206,894

 

 

 

128,046,895

 

 

 

172,206,177

 

 

 

126,323,921

 

Statements of Comprehensive Loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

$

(5,564,710

)

 

$

(6,850,534

)

 

$

(11,493,873

)

 

$

(15,676,349

)

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized loss on marketable securities, net of tax

 

(24,715

)

 

 

 

 

 

(58,557

)

 

 

 

Comprehensive loss

$

(5,589,425

)

 

$

(6,850,534

)

 

$

(11,552,430

)

 

$

(15,676,349

)

 

The Notes to Condensed Consolidated Financial Statements are an integral part of these statements.

 

4


Table of Contents

Tyme Technologies, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders’ Equity

For the Three and Six Months Ended September 30, 2021 and 2020

(Unaudited)

 

 

 

Common Stock

 

 

Additional

 

 

 

 

 

 

Accumulated Other

 

 

Total

 

 

 

Shares

 

 

Amount

 

 

Paid-in

Capital

 

 

Accumulated Deficit

 

 

Comprehensive Loss

 

 

Stockholders'

Equity

 

Balance, April 1, 2021

 

 

172,200,644

 

 

$

17,222

 

 

$

238,572,442

 

 

$

(136,794,015

)

 

$

 

 

$

101,795,649

 

Proceeds from the exercise of stock options

 

 

6,250

 

 

 

1

 

 

 

6,187

 

 

 

 

 

 

 

 

 

6,188

 

Stock based compensation

 

 

 

 

 

 

 

 

643,665

 

 

 

 

 

 

 

 

 

643,665

 

Unrealized loss on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(33,842

)

 

 

(33,842

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(5,929,163

)

 

 

 

 

 

(5,929,163

)

Balance, June 30, 2021

 

 

172,206,894

 

 

$

17,223

 

 

$

239,222,294

 

 

$

(142,723,178

)

 

$

(33,842

)

 

$

96,482,497

 

Stock based compensation

 

 

 

 

 

 

 

 

616,227

 

 

 

 

 

 

 

 

 

616,227

 

Unrealized loss on available-for-sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(24,715

)

 

 

(24,715

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(5,564,710

)

 

 

 

 

 

(5,564,710

)

Balance, September 30, 2021

 

 

172,206,894

 

 

$

17,223

 

 

$

239,838,521

 

 

$

(148,287,888

)

 

$

(58,557

)

 

$

91,509,299

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, April 1, 2020

 

 

123,312,252

 

 

$

12,333

 

 

$

126,828,055

 

 

$

(107,815,252

)

 

$

 

 

$

19,025,136

 

Issuance of common stock from at-the-market financing facility, net of associated expenses of $120,790

 

 

891,944

 

 

 

89

 

 

 

1,171,497

 

 

 

 

 

 

 

 

 

1,171,586

 

Warrant to share exchange

 

 

2,406,250

 

 

 

241

 

 

 

3,393,534

 

 

 

 

 

 

 

 

 

3,393,775

 

Stock based compensation

 

 

 

 

 

 

 

 

1,068,696

 

 

 

 

 

 

 

 

 

1,068,696

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(8,825,815

)

 

 

 

 

 

(8,825,815

)

Balance, June 30, 2020

 

 

126,610,446

 

 

$

12,663

 

 

$

132,461,782

 

 

$

(116,641,067

)

 

$

 

 

$

15,833,378

 

Issuance of common stock from at-the-market financing facility, net of associated expenses of $166,918

 

 

3,561,995

 

 

 

356

 

 

 

4,634,192

 

 

 

 

 

 

 

 

 

4,634,548

 

Stock based compensation

 

 

 

 

 

 

 

 

883,929

 

 

 

 

 

 

 

 

 

883,929

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(6,850,534

)

 

 

 

 

 

(6,850,534

)

Balance, September 30, 2020

 

 

130,172,441

 

 

$

13,019

 

 

$

137,979,903

 

 

$

(123,491,601

)

 

$

 

 

$

14,501,321

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The Notes to Condensed Consolidated Financial Statements are an integral part of these statements.

 

 

5


Table of Contents

 

Tyme Technologies, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

 

 

Six Months Ended                   September 30,

 

 

 

2021

 

 

2020

 

Cash flows from operating activities

 

 

 

 

 

 

 

 

Net loss

 

$

(11,493,873

)

 

$

(15,676,349

)

Adjustments to reconcile net loss to net cash used in operating activities

 

 

 

 

 

 

 

 

Depreciation

 

 

 

 

 

2,590

 

Amortization of employees, directors and consultants stock options

 

 

1,259,892

 

 

 

1,952,625

 

Change in fair value of warrant liability

 

 

(1,069,309

)

 

 

2,773,699

 

Gain on warrant exchange

 

 

 

 

 

(2,228,697

)

Net amortization of premiums and discounts on marketable securities

 

 

722,493

 

 

 

 

Gain on call redemption of marketable securities

 

 

(109

)

 

 

 

Change in operating assets and liabilities:

 

 

 

 

 

 

 

 

Prepaid clinical costs

 

 

958,361

 

 

 

(535,376

)

Prepaid expenses and other assets

 

 

425,138

 

 

 

500,304

 

Operating lease right-of-use asset

 

 

18,075

 

 

 

132,974

 

Accounts payable and other current liabilities

 

 

(503,259

)

 

 

1,550,056

 

Severance payable

 

 

(280,483

)

 

 

(183,906

)

Accrued bonuses

 

 

(299,513

)

 

 

(1,017,189

)

Operating lease liability

 

 

(17,764

)

 

 

(34,830

)

Net cash used in operating activities

 

 

(10,280,351

)

 

 

(12,764,099

)

 

 

 

 

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

 

 

 

 

Purchases of marketable securities

 

 

(74,516,729

)

 

 

 

Proceeds from maturities of marketable securities

 

 

6,490,083

 

 

 

 

Net cash used in investing activities

 

 

(68,026,646

)

 

 

 

 

 

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

 

 

Insurance note payments

 

 

 

 

 

(343,374

)

Proceeds from registered offerings, net of issuance costs

 

 

 

 

 

5,806,134

 

Proceeds from exercise of stock options

 

 

6,188

 

 

 

 

Net cash provided by financing activities

 

 

6,188

 

 

 

5,462,760

 

 

 

 

 

 

 

 

 

 

Net decrease in cash and cash equivalents

 

 

(78,300,809

)

 

 

(7,301,339

)

 

 

 

 

 

 

 

 

 

Cash and cash equivalents – beginning

 

 

107,516,420

 

 

 

26,700,416

 

Cash and cash equivalents – ending

 

$

29,215,611

 

 

$

19,399,077

 

 

 

 

 

 

 

 

 

 

Supplemental Cash Flow Information:

 

 

 

 

 

 

 

 

Interest

 

$

40,627

 

 

$

55,356

 

Income taxes

 

$

 

 

$

 

 

 

 

 

 

 

 

 

 

Noncash investing and financing activities:

 

 

 

 

 

 

 

 

Cashless exchange of April 2019 Warrants to purchase 5,833,333 shares of common stock for 2,406,250 shares in May 2020.

 

$

 

 

$

 

Cashless exchange of April 2019 Warrants to purchase 2,166,667 shares of common stock for May 2020 Warrant to purchase the same number of shares common stock.

 

$

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The Notes to Condensed Consolidated Financial Statements are an integral part of these statements.

 

 

 

6


Table of Contents

 

Tyme Technologies, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

September 30, 2021

(Unaudited)

Note 1. Nature of Business

 

Tyme Technologies, Inc. is a Delaware corporation headquartered in Bedminster, New Jersey, with a wholly-owned subsidiary, Tyme Inc. (together, “TYME” or the “Company”). The majority of the Company’s research, development and other business activities are conducted by Tyme Inc., which was incorporated in Delaware in 2013.

 

TYME is an emerging biotechnology company developing CMBTsTM that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also maintaining patients’ quality of life through relatively low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic requirements to cause cancer cell death.

 

The Company is currently focused on developing its novel compound, SM-88. The Company believes that early clinical results demonstrated by SM-88 in multiple advanced cancers, including pancreatic, prostate, sarcomas and breast, reinforce the potential of its emerging CMBT™ pipeline.

 

Ongoing Studies

 

Precision Promise Trial- SM-88 with MPS as 2nd line therapy in metastatic pancreatic cancer

 

The Company has partnered with PanCAN to study SM-88 in an adaptive randomized Phase II/III trial with registration intent known as Precision PromiseSM. The objective of Precision Promise is to expedite the study and approval of promising therapies for pancreatic cancer by bringing multiple stakeholders together, including academic, industry and regulatory entities. In this trial, which began in early 2020, SM-88 (with the conditioning agents MPS) is being studied as monotherapy in a treatment arm for patients who have failed one prior line of chemotherapy. PanCAN is sponsoring Precision Promise and providing funding and other support. While TYME’s SM-88 is included in the trial, the Company does not oversee, conduct or control the trial. As of September 30, 2021, there were fifteen participating sites in the Precision Promise trial. PanCAN has approved adding 15 additional sites, with five new sites planned to open in early calendar year 2022 and an additional ten sites expected to open by the end of calendar year 2022.

 

Although we do not have details of the enrollment of the SM-88 cohort, the next likely event in the trial would be a determination of potential “graduation” from the Phase II portion of the trial to the Phase III confirmatory portion of the trial. We expect to learn if the trial advances to Phase III during the second half of calendar year 2022.

 

OASIS Trial in metastatic HR+/HER2- breast cancer

 

This quarter, the Company announced an agreement with Georgetown University to support a Phase II trial, OASIS, for SM-88 in patients with metastatic breast cancer who have HR+ and HER2- disease (“HR+/HER2-”) . This represents approximately 73% of the annual breast cancer diagnoses in the US each year. The OASIS trial is an investigator-initiated prospective open-label Phase II trial evaluating the efficacy and safety of SM-88 with MPS for the treatment of metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor. This trial is designed as a two-stage trial, enrolling up to 50 patients to receive SM-88 with MPS without additional therapies in patients who have failed or progressed after receiving two hormonal agents and a CDK4/6 inhibitor. The primary endpoint of this trial is ORR, with secondary endpoints including DOR, CBR at >24 weeks, PFS, and safety. The trial will be conducted at Georgetown University at a total of five sites within the Georgetown/MEDSTAR system located in Washington DC, Maryland, and New Jersey. Patient enrollment began this quarter with the first patient dosed in September. We plan to provide an update on the OASIS breast cancer study during the first half of calendar year 2023.

 

HoPES Trial in sarcoma

 

In early 2020, the open-label Phase 2 investigator-sponsored trial of SM-88 therapy in sarcoma, HoPES, opened. This trial has two cohorts, each expecting to enroll 12 patients. The first is SM-88 with MPS as salvage treatment in patients with mixed rare sarcomas, and the other is SM-88 with MPS as maintenance treatment for patients with metastatic Ewing’s sarcoma who had not progressed on prior therapy. The primary objectives are to measure ORR and PFS. Secondary objectives include DOR, OS, CBR using RECIST, and incidence of treatment-emergent AEs. The Joseph Ahmed Foundation is sponsoring this trial and the trial is being conducted by PI Dr. Chawla at the Sarcoma Oncology Center in Santa Monica, CA. We anticipate that the trial will complete enrollment by the end of the first half of calendar year 2022.

 

7


Table of Contents

Preclinical Pipeline Programs

The Company has begun a comprehensive translational preclinical program focused on SM-88 MOA and Biomarker Identification/Validation. We have engaged Evotec, a leading global research and development company, to aid in the execution of these activities and are also incorporating several complementary academic collaborations into this multi-faceted program. The overall goal of these activities is to potentially identify actionable biomarkers of sensitivity and activity to SM-88 in various cancers, complementary combination drugs strategies for SM-88, and other cancer metabolism targets that could be targeted for treatment. Later in the program, the Company intends to incorporate liquid and tumor biopsies into future clinical trials to contribute to the biomarker identification. TYME anticipates this preclinical engagement will have several stages, and that it is likely to last through this fiscal year and also into future periods.

 

TYME-18 is a CMBT compound under development that is delivered intratumorally. TYME-18 leverages a member of the bile acid family to create a potential treatment for inoperable tumors. Preliminary observations of the local administration of TYME-18, a combination of a proprietary surfactant system and natural sulfonic acid, suggested its potential as an important regulator of energy metabolism that may impede the ability of tumors to increase in size, which, in addition to its lytic functionality, could prove useful in difficult-to-treat cancers. In initial preclinical xenograft mouse studies, TYME-18 was able to completely resolve over 90 percent (11/12 mice) of established colorectal tumors within 12 days versus an average of over 600 percent growth in the control animals. 

 

TYME-19 is an oral synthetic member of the bile acid family. The Company also uses bile acids in its anticancer drug candidate, TYME-18. Because of its expertise in bile acids and their effects, the Company was able to identify TYME-19 as a well-characterized bile acid with potential antiviral properties. Bile acids have primarily been used for liver disease; however, like all steroids, they are messenger molecules that modulate a number of diverse critical cellular processes. Bile acids can modulate lipid and glucose metabolism and can remediate dysregulated protein folding, with potentially therapeutic effects on cardiovascular, neurologic, immune, and other metabolic systems. Some agents in this class have also previously shown antiviral properties. In in vitro preclinical testing, TYME-19 prevented COVID-19 viral replication at doses without meaningful cytotoxicity to the treated cells. Previous independent preclinical research has also shown select bile acids may have had broad antiviral activity.

 

Tumor Targeting Technology

 

TYME has developed a technology (“Tumor Targeting Technology”) by which the tyrosine isomer L metyrosine (L-α-methylparatyrosine) can be fused with a second therapeutic agent in a manner that creates a fusion compound that may allow targeted accumulation of the treatment by the cancer cells in a novel manner. This method of tumor targeting is predicated on the metabolic phenomenon in which cancer cells consume higher quantities of non-essential amino acids, including tyrosine, from their surrounding environment to support their growth because they cannot make enough of these amino acids. Tumor Targeting Technology is an investigational approach in the preclinical phase of development that is not approved in the U.S. for any disease indication and requires further preclinical development, which the Company plans to initiate this year.

 

Discontinuing Programs

 

TYME-88-PANC (Part 2) (third-line Metastatic Pancreatic Cancer)

 

In fiscal year 2020, TYME launched its pivotal study for SM-88 in the third-line treatment of pancreatic cancer through an amendment to our ongoing TYME-88-Panc trial (Part 2), with the first patient dosed in the third quarter of the fiscal year. As described previously, the COVID-19 pandemic significantly impacted enrollment of this trial such that it appeared it was likely to complete enrollment in a similar timeline to the second-line Precision Promise pancreatic cancer trial. There was also a higher than expected dropout rate of patients randomized to the chemotherapy control arm, which could have potentially impacted the interpretative and regulatory utility of the data.

 

Following the strategic review discussed below, considering, in part, the timeline and regulatory utility for this trial compared to the parallel Precision Promise trial and concentration of investment in this specific cancer, management concluded that it would be best to focus on the second-line Precision Promise trial, which offers treatment options to patients earlier in their disease and includes tumor biopsy and biomarker analyses that align with the Company’s overall strategic focus on identifying targeted therapies.

 

Therefore, the Company decided to stop enrollment and begin the process of closing down the trial. Patients currently on therapy will be allowed to continue treatment until progression or unacceptable toxicity. The closing of this trial is expected to require several months to complete. In the six months ended September 30, 2021, the Company expensed $843,000 of estimated closeout costs. The trial’s remaining ongoing expense to the Company is approximately $1.2 million, and is expected to be incurred over the next nine months.

 

8


Table of Contents


The accompanying condensed consolidated financial statements include the results of operations of Tyme Technologies, Inc. and its wholly-owned subsidiary, Tyme, Inc.

Liquidity

 

The condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has historically funded its operations primarily through equity offerings.

 

In February 2021, the Company raised $100 million in gross proceeds through a registered direct offering of 40,000,000 shares of its common stock, at a purchase price of $2.50 per share. The Company incurred $6.2 million of related costs, which offset such proceeds.

 

On January 7, 2020, the Company entered into an SPA with Eagle Pharmaceuticals, Inc. (“Eagle”), pursuant to which the Company raised $20.0 million through the issuance and sale to Eagle of 10,000,000 shares of common stock, at a price of $2.00 per share.

 

On October 18, 2019, TYME entered into an Open Market Sale AgreementSM (as amended, the “Sale Agreement”) with Jefferies LLC (“Jefferies”) as sales agent, pursuant to which the Company may, from time to time, sell shares of common stock through Jefferies having an aggregate offering price of up to $30.0 million (the “Jefferies ATM”). The Company did 0t sell any shares through the Jefferies ATM during the six months ended September 30, 2021. In the six months ended September 30, 2020, the Company raised approximately $6.1 million in aggregate gross proceeds through the Jefferies ATM and paid commissions and expenses of $0.3 million. At September 30, 2021, there remained approximately $22.2 million of availability to sell shares through the Jefferies ATM.

 

The proceeds of the aforementioned offerings are being used by the Company for continued clinical studies, drug commercialization and development activities and other general corporate and operating expenses.

       

For the six months ended September 30, 2021, the Company had negative cash flow from operations of $10.3 million and net loss of $11.5 million, which included non-cash expenses of $1.3 million related to non-cash equity compensation and $0.7 million net amortization expense of premiums and discounts on marketable securities, offset by $1.1 million income change in fair value of warrant liability. As of September 30, 2021, the Company had working capital of approximately $72.6 million.

Management has concluded that substantial doubt does not exist regarding the Company’s ability to satisfy its obligations as they come due during the twelve-month period following the issuance of these financial statements. This conclusion is based on the Company’s assessment of qualitative and quantitative conditions and events, considered in aggregate as of the date of issuance of these financial statements that are known and reasonably knowable. Among other relevant conditions and events, the Company has considered its operational plans, liquidity sources, obligations due or expected, funds necessary to maintain the Company’s operations, and potential adverse conditions or events as of the issuance date of these financial statements.

Note 2. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated financial statements and related notes should be read in conjunction with the consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the year ended March 31, 2021 filed with the SEC on June 10, 2021 (the “2021 10-K”). The condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are necessary to present fairly the results for the interim periods. All such adjustments are of a normal and recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year.

The Company’s condensed consolidated financial statements include the accounts of Tyme Technologies, Inc. and its subsidiary, Tyme Inc. All intercompany transactions and balances have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in ASC and ASU of the FASB.

 

9


Table of Contents

Significant Accounting Policies

 

The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended March 31, 2021 included in the Company’s 2021 10-K.

Cash and cash equivalents

Cash and cash equivalents include demand deposit accounts, money market funds and municipal debt securities. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash equivalents are stated at fair value.

Marketable Securities

All of the Company's marketable securities are debt securities and are classified as available-for-sale in accordance with the ASC Topic 320, “Investments - Debt and Equity Securities.” Available for sale securities are carried at fair value and reported in cash equivalents and marketable securities. Marketable securities are further classified as short-term or long-term based on maturity dates and the Company’s intent in line with its investment policy to hold the securities to scheduled maturity. Unrealized gains and losses on available-for-sale securities are excluded from net loss and reported in accumulated other comprehensive loss as a separate component of stockholders' equity. Other income includes interest, dividends, amortization of purchase premiums and discounts, gain and losses on sale (or redemptions) of securities and other-than-temporary declines in the fair value of securities, if any.

For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. In making this assessment, the Company considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for a credit loss is recorded on our consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis. Impairment that has not been recorded through an allowance for credit losses is recorded through other comprehensive loss, net of applicable taxes.

Fair Value of Financial Instruments

The carrying amounts reported in the Company’s condensed consolidated financial statements for cash, accounts payable, and other current liabilities approximate their respective fair values because of the short-term nature of these accounts. The fair value of the severance payable approximates the carrying value, which represents the present value of future severance payments. Cash equivalents, marketable securities and the derivative warrant liability are recorded at fair value.

Fair value is defined as the price that would be received if selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The fair value hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets (Level 1), and the lowest priority to unobservable inputs (Level 3). The Company’s financial assets are classified within the fair value hierarchy based on the lowest level of inputs that is significant to the fair value measurement. The three levels of the fair value hierarchy, and their applicability to the Company’s financial assets, are described below.

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date of identical, unrestricted assets.

Level 2: Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security.

Level 3: Pricing inputs are unobservable for the assets. Level 3 assets include private investments that are supported by little or no market activity. Level 3 valuations are for instruments that are not traded in active markets or are subject to transfer restrictions and may be adjusted to reflect illiquidity and/or non-transferability, with such adjustment generally based on available market evidence. In the absence of such evidence, management’s best estimate is used.

An adjustment to the pricing method used within either Level 1 or Level 2 inputs could generate a fair value measurement that effectively falls in a lower level in the hierarchy. The Company had no material re-measurements of fair value with respect to financial

 

10


Table of Contents

assets and liabilities, during the periods presented, other than those assets and liabilities that are measured at fair value on a recurring basis see Note 6.

Derivative Warrant Liability

Certain freestanding common stock warrants that are related to the issuance of common stock are classified as liabilities and recorded at fair value due to characteristics that require liability accounting, primarily the obligation to issue registered shares of common stock upon notification of exercise or certain price protection provisions. Warrants of this type are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of other income (expense) in the condensed consolidated statement of operations. As noted in Note 8, Stockholders’ Equity, the Company classifies a warrant to purchase shares of its common stock as a liability on its condensed consolidated balance sheet if the warrant is a free-standing financial instrument that contains certain price protection features that cause the warrants to be treated as derivatives or requires the issuance of registered common shares upon exercise. Each warrant of this type is initially recorded at fair value on date of grant using the Monte Carlo simulation model or the Black-Scholes model, and is subsequently re-measured to fair value at each subsequent balance sheet date. Changes in fair value of the warrant are recognized as a component of other income (expense) in the consolidated statement of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant. The Company utilizes Level 3 fair value criteria to measure the fair value of the warrants (see Note 6).

Risks and Uncertainties

The Company is subject to those risks associated with any biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants, as well as third party contractors.

Current Economic Conditions

The novel coronavirus (COVID-19) pandemic, and actions taken by governments and others to reduce its spread, has negatively impacted the global economy, financial markets, and the Company’s industry and has disrupted day-to-day life and business operations. Even as certain restrictions have been lifted, new processes implemented and vaccines have become more widely available and administered, spikes in infections (including the spread of new variants) continue to be experienced as conditions evolve and fluctuate around the world. The extent to which the continuing COVID-19 pandemic impacts our product candidates and business, including patients’ willingness to participate and remain in clinical trials, the timing of meeting enrollment expectations, the ability of our third-party partners to remain operational and our access to capital markets and financing sources, depends on numerous evolving factors that are highly uncertain, cannot be accurately predicted, and may be significant.

Recent Accounting Pronouncements

 

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Amendments include removal of certain exceptions to the general principles of ASC 740 , Income Taxes and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. ASU 2019-12 is effective for public business entities for annual reporting periods beginning after December 15, 2020, and interim periods within those reporting periods. The Company adopted the pronouncement as of April 1, 2021 and the adoption of this standard did not have a material impact on its condensed consolidated financial statements and disclosures.

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) and has since modified the standard with several ASUs (collectively, “Topic 326”). Topic 326 requires companies to present a financial asset (or a group of financial assets) measured at amortized cost and available for sale debt securities net of the amounts expected to be collected. Prior U.S. GAAP delayed recognition of the full amount of credit losses until the loss was probable of occurring. Under this ASU, the income statement will reflect an entity’s current estimate of all expected credit losses. The measurement of expected credit losses will be based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down of the security. Early adoption is permitted. The guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted the pronouncement as of April 1, 2021 and the adoption of this standard did not have a material impact on its condensed consolidated financial statements and disclosures.

 

11


Table of Contents

 

In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40). ASU No. 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the new guidance modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation.

 

The amendments in ASU No. 2020-06 are effective for public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. FASB also specified that an entity should adopt the guidance as of the beginning of its annual fiscal year and is not permitted to adopt the guidance in an interim period. The Company adopted the pronouncement as of April 1, 2021 and the adoption of this standard did not have a material impact on its condensed consolidated financial statements and disclosures.

 

Note 3. Net Loss Per Common Share

The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated:

 

 

 

Three Months Ended

September 30,

 

 

Six Months Ended                   September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Basic and diluted net loss per common share calculation:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(5,564,710

)

 

$

(6,850,534

)

 

$

(11,493,873

)

 

$

(15,676,349

)

Weighted average common shares outstanding — basic and diluted:

 

 

172,206,894

 

 

 

128,046,895

 

 

 

172,206,177

 

 

 

126,323,921

 

Net loss per share of common stock — basic and diluted

 

$

(0.03

)

 

$

(0.05

)

 

$

(0.07

)

 

$

(0.12

)

 

The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic net loss per share is computed by dividing net loss attributable to the Company by the weighted average number of shares of Company Common Stock outstanding for the period, and diluted EPS is computed by including common stock equivalents outstanding for the period. During the periods presented, the calculation excludes any potential dilutive common shares and any equivalents as they would have been anti-dilutive.

 

The following outstanding securities at September 30, 2021 and 2020 have been excluded from the computation of diluted weighted average shares outstanding, as they are anti-dilutive:

 

 

 

September 30,

 

 

 

2021

 

 

2020

 

Stock options

 

 

14,697,448

 

 

 

14,577,732

 

Warrants

 

 

3,104,318

 

 

 

3,104,318

 

Total

 

 

17,801,766

 

 

 

17,682,050

 

 

Note 4. Accounts Payable and Other Current Liabilities

Accounts payable (including accounts payable to a related party – see Note 11) and other current liabilities consisted of the following:

 

 

 

September 30,

2021

 

 

March 31,

2021

 

Legal

 

$

147,596

 

 

$

454,139

 

Consultant and professional services

 

 

65,679

 

 

 

176,957

 

Accounting and auditing

 

 

2,822

 

 

 

55,349

 

Research and development

 

 

2,662,905

 

 

 

2,657,202

 

Board of Directors and Scientific Advisory Board Compensation

 

 

429,281

 

 

 

435,594

 

Other

 

 

30,848

 

 

 

63,149

 

Total

 

$

3,339,131

 

 

$

3,842,390

 

 

 

12


Table of Contents

 

Note 5. Severance Payable

During the six months ended September 30, 2021, the Company entered into Separation and General Release Agreements with 2 employees. The agreements provide separation benefits which the Company recorded as severance expense. In April 2021, the Company entered into a Separation and General Release Agreement related to the separation of employment of its then-Chief Medical Officer as of March 31, 2021. The agreement provides for separation benefits which the Company recorded as severance expense for the year ended March 31, 2021. On March 15, 2019, the Company entered into a Release Agreement related to the separation of employment of its then-Chief Operating Officer. The agreement provides for salary continuance for five years, reimbursement of health benefits for three years and a modification to his outstanding stock options to extend the post-termination exercise period for his vested options from three months to five years. The Company recorded severance expense at its present value of $2.5 million (using a discount rate of 6%) for the year ended March 31, 2019, including $0.4 million relating to the stock option modification. The aggregate severance liability payable as of September 30, 2021 and March 31, 2021 was $1.3 million and $1.6 million, respectively.

6. Fair Value Measurements


The Company has segregated all financial assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. Transfers are calculated on values as of the transfer date. There were no transfers between Levels 1, 2 and 3 during the six months ended September 30, 2021.

 

The Company’s financial instruments measured at fair value on a recurring basis as of September 30, 2021 and March 31, 2021 are as follows:

 

 

 

 

 

 

Quoted

prices in

active

markets

 

 

Significant

other

observable

inputs

 

 

Significant

unobservable

inputs

 

September 30, 2021

 

Total

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Financial assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

6,726,462

 

 

$

6,726,462

 

 

$

 

 

$

 

Marketable Securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

16,267,438

 

 

 

 

 

 

16,267,438

 

 

 

 

Municipal debt securities

 

 

30,027,345

 

 

 

 

 

 

30,027,345

 

 

 

 

Long-term

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

 

7,383,159

 

 

 

 

 

 

7,383,159

 

 

 

 

Municipal debt securities

 

 

12,986,229

 

 

 

 

 

 

12,986,229

 

 

 

 

 

 

$

73,390,633

 

 

$

6,726,462

 

 

$

66,664,171

 

 

$

 

Financial liability

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liability

 

$

862,612

 

 

$

 

 

$

 

 

$

862,612

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial liability

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrant liability

 

$

1,931,921

 

 

$

 

 

$

 

 

$

1,931,921

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The fair value of cash equivalents held in money market funds is determined based on “Level 1” inputs. Marketable securities classified as Level 2 within the valuation hierarchy consist of corporate debt securities and municipal debt securities. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs.

 

 

13


Table of Contents

 

The fair value measurement for the warrant issued in conjunction with the Exchange Agreements (see Note 8 for transaction details) (the “May 2020 Warrant”) is based on significant inputs not observable in the market and is classified as Level 3 liability as of September 30, 2021 and March 31, 2021. The fair value of the May 2020 Warrant was determined using a Black Scholes model and included significant unobservable inputs such as volatility. The model also incorporated several observable assumptions at each valuation date including: the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk free interest rate over the term.

 

The following table details key inputs and assumptions used to estimate the fair value of the May 2020 Warrant as of September 30, 2021 and March 31, 2021 using a Black Scholes model:

 

 

 

May 2020 Warrant

 

 

May 2020 Warrants

 

 

 

September 30, 2021

 

 

March 31, 2021

 

Stock price

 

$

1.03

 

 

$

1.78

 

Volatility

 

 

89

%

 

 

78

%

Remaining term (years)

 

2.51

 

 

 

3.01

 

Expected dividend yield

 

 

 

 

 

 

Risk-free rate

 

 

0.41

%

 

 

0.35

%

 

The following table summarizes activity for liabilities measured at fair value using Level 3 significant unobservable inputs:

 

 

 

September 30,  2021

 

Beginning balance, March 31, 2021

 

$

1,931,921

 

Change in fair value of May 2020 Warrant liability

 

 

(1,069,309

)

Ending balance, September 30, 2021

 

$

862,612

 

 

Note 7. Available-for-Sale-Securities

 

The following table summarizes available-for-sale securities recorded in cash and cash equivalents or marketable securities as of September 30, 2021:

 

 

 

September 30, 2021

 

 

 

Amortized cost

 

 

Gross Unrealized Gains

 

 

Gross Unrealized Loss

 

 

Fair Value

 

Money market funds

 

$

6,726,462

 

 

$

 

 

$

 

 

$

6,726,462

 

Corporate debt securities

 

 

23,683,402

 

 

 

381

 

 

 

(33,186

)

 

 

23,650,597

 

Municipal debt securities

 

 

43,039,326

 

 

 

4,618

 

 

 

(30,370

)

 

 

43,013,574

 

Total

 

$

73,449,190

 

 

$

4,999

 

 

$

(63,556

)

 

$

73,390,633

 

 

The following table summarizes the classification of available-for-sale securities:

 

 

 

September 30, 2021

 

 

March 31, 2021

 

Cash and cash equivalents

 

$

6,726,462

 

 

$

 

Marketable securities

 

 

66,664,171

 

 

 

 

Total

 

$

73,390,633

 

 

$

 

 

The following table summarizes our portfolio of available-for-sale securities by contractual maturity:

 

 

 

 

Less than 12 months

 

 

12 months or Longer

 

 

Total

 

 

 

Fair Value

 

 

Net Unrealized Losses

 

 

Fair Value

 

 

Net Unrealized Losses

 

 

Fair Value

 

 

Net Unrealized Losses

 

Money market funds

 

$

6,726,462

 

 

$

 

 

$

 

 

$

 

 

$

6,726,462

 

 

$

 

Corporate debt securities

 

 

16,267,439

 

 

 

(18,012

)

 

 

7,383,158

 

 

 

(14,793

)

 

 

23,650,597

 

 

 

(32,805

)

Municipal debt securities

 

 

30,027,345

 

 

 

(9,837

)

 

 

12,986,229

 

 

 

(15,915

)

 

 

43,013,574

 

 

 

(25,752

)

Total

 

$

53,021,246

 

 

$

(27,849

)

 

$

20,369,387

 

 

$

(30,708

)

 

$

73,390,633

 

 

$

(58,557

)

 

14


Table of Contents

 

 

Note 8. Stockholders’ Equity

 

Exchange Agreements

 

On May 20, 2020, the Company entered into exchange agreements with holders (the “Holders”) of the warrants issued in April 2019 (the “April 2019 Warrants”). The April 2019 Warrants were offered and issued pursuant to the Company’s previous shelf registration statement on Form S-3 (File No. 333-211489).

 

Pursuant to exchange agreements (the “Share Exchange Agreements”) with Holders of the April 2019 Warrants to purchase 5,833,333 shares of Common Stock in the aggregate, the Company issued an aggregate of 2,406,250 shares of common stock (the “Exchange Shares”) in exchange for such April 2019 Warrants. Concurrently therewith, each such Holder executed and delivered to the Company a leak-out agreement (a “Share Leak-Out Agreement”) that contained trading restrictions with respect to the Exchange Shares, which (i) for the first 90 days, prohibit any sales of Exchange Shares, (ii) for the subsequent 90 days, limit sales of Exchange Shares on any day to 2.5% of that day’s trading volume of Common Stock, and (iii) prohibit new short positions or short sales on Common Stock for the combined 180 day period.

 

The Company also entered into an exchange agreement (the “Warrant Exchange Agreement”) with another Holder of April 2019 Warrants to purchase 2,166,667 shares of Common Stock in the aggregate. Pursuant to the Warrant Exchange Agreement, the Company issued such Holder a new warrant (the “May 2020 Warrant”) to purchase the same number of shares of Common Stock. The May 2020 Warrant has the same expiration date, April 2, 2024, as the April 2019 Warrants, but has an exercise price of $1.80 and does not include certain price protection, anti-dilution provisions or other restrictions on Company action from the April 2019 Warrants. Concurrently therewith, such Holder executed and delivered to the Company a leak-out agreement that contained trading restrictions on sales of Common Stock issued upon exercise of the May 2020 Warrant that are substantially similar to the restrictions on Exchange Shares in the Share Leak-Out Agreement, provided that the leak-out restrictions will only apply to the first 893,750 shares of Common Stock issued pursuant to the May 2020 Warrant.

 

The April 2019 Warrants were remeasured as of May 20, 2020, before the exchange, using the Monte Carlo pricing simulation resulting in a fair value of approximately $7.3 million, and the change in fair value from March 31, 2020 to the fair value before the exchange of approximately $3.7 million was recorded as an expense component of other income (expense) within the condensed consolidated statement of operations. The key assumptions in applying the Monte Carlo simulation model were as follows: $1.70 stock price, 73% volatility, 3.87 years remaining term, 0.28% risk free rate and the probability of fundamental transactions occurring.

 

At May 20, 2020, the fair value of the 2,406,250 shares issued under the Share Exchange Agreements was approximately $3.4 million and resulted in a gain on exchange of approximately $1.9 million.

 

The exercise price of the May 2020 Warrant is subject to adjustment upon the occurrence of specific events, including stock dividends, stock splits, combinations and reclassifications of the Company’s Common Stock.

 

The Company determined that the May 2020 Warrant should be recorded as a derivative liability on the condensed consolidated balance sheet due to the May 2020 Warrant’s contractual provisions requiring issuance of registered common shares upon exercise. At May 20, 2020, the May 2020 Warrant was recorded at the fair value of $1.7 million as determined using the Black Scholes model and the change in fair value before and after the exchange of $0.3 million was recorded as a gain on warrant exchange as a component of other income (expense) within the condensed consolidated statement of operations. The key assumptions in applying the Black Scholes model were as follows: $1.64 stock price, 73% volatility, 3.87 years remaining term, 0.27% risk free rate and 7% discount for lack of marketability. The change in fair value of the May 2020 Warrant from May 20, 2020 through September 30, 2020 of $0.9 million income was recorded as a component of other income (expense) within the condensed consolidated statement of operations.

 

The following summarizes the common stock warrant activity for the six months ended September 30, 2021:

 

 

 

Warrant

Shares of

Common Stock

 

 

Weighted Average Exercise Price

 

Outstanding at March 31, 2021

 

 

3,104,318

 

 

$

2.77

 

Granted

 

 

 

 

 

 

Exchanged

 

 

 

 

 

 

Outstanding at September 30, 2021

 

 

3,104,318

 

 

$

2.77

 

 

At each of September 30, 2021 and March 31, 2021, 3,074,551, of common stock purchase warrants relating to SPAs were outstanding and exercisable.

 

15


Table of Contents

Warrants

 

The Company has warrants to purchase its common stock outstanding as of September 30, 2021, as follows:

 

Issued

 

Classification

 

Warrants

Outstanding

 

 

Exercise

Price

 

 

Expiration

December 2015

 

Equity

 

 

446,500

 

 

$

5.00

 

 

December 2025

February 2016

 

Equity

 

 

461,384

 

 

$

5.00

 

 

February 2026

July 2016

 

Equity

 

 

29,767

 

 

$

5.00

 

 

June 2026

May 2020

 

Liability

 

 

2,166,667

 

 

$

1.80

 

 

April 2024

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

At-the-Market Financing Facility

 

On October 18, 2019, the Company entered into the Sale Agreement with Jefferies, which was amended on August 12, 2020, pursuant to which the Company may, from time to time, sell shares of common stock, having an aggregate offering price of up to $30.0 million through Jefferies, as the Company’s sales agent. As indicated in the amendment, the shares will be offered and sold by the Company pursuant to its currently effective Registration Statement on Form S-3, as amended (Reg. No. 333-245033). Any sales of common stock pursuant to the Sales Agreement will be made by methods deemed to be an “at-the-market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. Jefferies will use commercially reasonable efforts to sell the shares from time to time, based on the instructions of the Company. The Company will pay Jefferies a commission rate of three percent (3%) of the gross proceeds from the sales of shares of Common Stock sold pursuant to the Sale Agreement. Under the Sale Agreement, the Company is not required to use the full available amount authorized and it may, by giving notice as specified in the Sale Agreement, terminate the Sale Agreement at any time.

 

The Company did 0t sell any shares through the Jefferies ATM during the six months ended September 30, 2021. During the six months ended September 30, 2020, the Company raised approximately $6.1 million in gross proceeds through the sale of 4,453,939 shares of Common Stock and incurred $0.3 million of related costs that offset the proceeds. At September 30, 2021, there remained approximately $22.2 million of availability to sell shares through the Jefferies ATM.   

 

Securities Purchase Agreement

 

On January 7, 2020, the Company and Eagle entered into the Eagle SPA, pursuant to which the Company issued and sold to Eagle 10,000,000 shares of common stock, at a price of $2.00 per share. The Eagle SPA provides that Eagle will, subject to certain conditions, make an additional payment of $20 million upon the occurrence of a milestone event, which is defined as the earlier of (i) achievement of the primary endpoint of OS in the TYME-88-Panc pivotal trial; (ii) achievement of the primary endpoint of OS in the PanCAN Precision Promise SM-88 registration arm; or (iii) FDA approval of SM-88 in any cancer indication. This payment would be split into a $10 million milestone cash payment and a $10 million investment in TYME at a 15% premium to the then prevailing market price. Eagle’s shares will be restricted from sale until the earlier of three months following the milestone event or the three-year anniversary of the agreement.

 

Registered Direct Offering

 

On February 8, 2021, the Company closed on its registered direct offering with several healthcare-focused institutional and other institutional investors (the “Purchasers”), pursuant to which the Company sold to the Purchasers an aggregate of 40,000,000 shares (the “Shares”) of common stock, $0.0001 par value per share. The Shares were sold at a purchase price of $2.50 per share for aggregate gross proceeds to the Company of $100 million, prior to deducting placement agent’s fees and other offering expenses payable by TYME. The Company incurred $6.2 million of related costs that offset such proceeds. The Shares were offered by the Company pursuant to an effective shelf registration statement on Form S-3, which was originally filed with the SEC on August 12, 2020 and was declared effective on September 2, 2020 (Reg. No. 333-245033). H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

 

 

16


Table of Contents

 

Note 9. Commitments and Contingencies

Contract Service Providers

In the course of the Company’s normal business operations, it enters into agreements and arrangements with contract service providers to assist in the performance of its research and development and clinical research activities. At September 30, 2021, the Company’s obligations to contract service providers, including PanCAN discussed below, were $3.2 million in the aggregate.

 

On April 1, 2020, the Company amended the Clinical Research Funding and Drug Supply Agreement dated October 9, 2018, with PanCAN, to enroll individuals diagnosed with pancreatic cancer in a platform style clinical research study. Stage 1 of the study was initiated in the fourth quarter of fiscal year 2020. As of September 30, 2021, after taking into consideration amounts already incurred, the remaining expense to the Company is approximately $3.0 million, subject to enrollment adjustments, and is expected to be incurred over the next year.

Purchase Commitments

The Company has entered into contracts with manufacturers to supply SM-88 and certain related conditioning agents, in order to achieve favorable pricing on supplied products. These contracts have non-cancellable elements related to the scheduled deliveries of these products in future periods. Payments are made by us to the manufacturer when the products are delivered and of acceptable quality. The outstanding future contract obligations structured to match clinical supply needs for the Company’s ongoing trials and registration activity are approximately $0.8 million and $3.2 million, respectively, at September 30, 2021.

 

Legal Proceedings

 

The Company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding against it that it believes could have a material adverse effect on the Company, its business, operating results or financial condition. From time to time, the Company may be involved in litigation, claims or other contingencies arising in the ordinary course of business. The Company would accrue a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company would not record a liability, but instead would disclose the nature and the amount of the claim, and an estimate of the loss or range of loss, if such estimate can be made. Legal fees are expensed as incurred.

 

Note 10. Leases

 

The Company has a lease for office space in New Jersey, which expires in February 2023.  

 

Total Company rent expense, including short term rentals, was approximately $14,000 and $28,000 for the three and six months ended September 30, 2021 and $64,000 and $141,000 for the three and six months ended September 30, 2020.  

 

Operating lease ROU assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease ROU assets and liabilities. The Company uses its incremental borrowing rate of 11.0% to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.

 

As of September 30, 2021, the future minimum lease payments under non-cancellable operating lease agreements for which the Company has recognized operating lease ROU assets and lease liabilities were as follows:

 

 

 

September 30, 2021

 

Fiscal year 2022

 

$

19,620

 

Fiscal year 2023

 

 

43,164

 

Total remaining lease payments

 

 

62,784

 

Less: present value adjustment

 

 

(4,634

)

Total operating lease liabilities

 

 

58,150

 

Less: current portion

 

 

(38,883

)

Operating lease liabilities, net of current portion

 

$

19,267

 

 

 

17


Table of Contents

 

 

Note 11. Related Party Transactions

 

Legal

 

Faegre Drinker Biddle & Reath (“Faegre Drinker”), formerly Drinker Biddle & Reath LLP (“DBR”), has provided legal services to the Company. The Company’s Chief Legal Officer and Corporate Secretary holds the consulting role “Senior Counsel” with Faegre Drinker. Legal fees incurred associated with Faegre Drinker were approximately $151,000 and $266,000 for the three and six months ended September 30, 2021, respectively, and $161,000 and $396,000 for the three and six months ended September 30, 2020. At September 30, 2021 and March 31, 2021, the Company had approximately $68,000 and $87,000, respectively, in accounts payable and accrued expenses payable to Faegre Drinker.

Note 12. Equity Incentive Plan

Stock Options

 

As of September 30, 2021, there was approximately $5.8 million of total unrecognized compensation expense related to non-vested stock options. The cost is expected to be recognized over the remaining weighted average service period of 3.1 years.

 

As of September 30, 2021, there were 7,441,131 shares available for grant under the Company’s 2015 Equity Incentive Plan and 2016 Director Plan.

 

Stock based compensation expense was recognized as follows:

 

 

 

Three Months Ended

September 30,

 

 

Six Months Ended                   September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

General and administrative

 

$

480,000

 

 

$

538,000

 

 

$

951,000

 

 

$

1,100,000

 

Research and development

 

 

136,000

 

 

 

346,000

 

 

 

309,000

 

 

 

853,000

 

Total

 

$

616,000

 

 

$

884,000

 

 

$

1,260,000

 

 

$

1,953,000

 

 

 

The Company uses the Black-Scholes option pricing model to determine the fair value of stock options granted. For employees and non-employees, the compensation expense is amortized on a straight-line basis over the requisite service period, which approximates the vesting period. The Company accounts for forfeitures as they occur, rather than estimating forfeitures as of an award’s grant date.

The expected volatility of options granted has been determined using the method described under ASC 718 using the expected volatility of similar companies. The expected term of options granted to employees, non-employees and consultants in the current fiscal period has been based on the term by using the simplified method as allowed under SAB No. 110 and ASU 2018-7.

 

The weighted average assumptions used to determine such values are presented in the following table:

 

 

 

September 30,

2021

 

 

September 30,

2020

 

Risk free interest rate

 

0.28% - 1.01%

 

 

0.17% - 0.40%

 

Expected volatility

 

97.11% - 105.37%

 

 

88.02% - 101.67%

 

Expected term (in years)

 

2.7 - 6.1

 

 

2.8  -  6.1

 

Dividend yield

 

 

0

%

 

 

0

%

 

18


Table of Contents

 

The following is a summary of the status of the Company’s stock options for the six months ended September 30, 2021:

 

 

 

Number of

Options

 

 

Weighted

Average

Exercise

Price

 

Outstanding at March 31, 2021

 

 

12,588,068

 

 

$

2.92

 

Granted

 

 

3,569,500

 

 

$

1.38

 

Cancelled/Forfeited

 

 

(1,453,870

)

 

$

4.34

 

Exercised

 

 

(6,250

)

 

$

0.99

 

Outstanding at September 30, 2021

 

 

14,697,448

 

 

$

2.40

 

Options exercisable at September 30, 2021

 

 

8,404,207

 

 

$

3.23

 

 

 

 

 

 

 

 

 

Stock Options Outstanding

 

 

Stock Options Vested

 

Range of

Exercise

Price

 

Number Outstanding at September 30,  2021

 

 

Weighted

Average

Exercise

Price

 

 

Weighted

Average

Remaining

Life

(Years)

 

 

Aggregate

Intrinsic

Value

 

 

Number

Vested at September 30,  2021

 

 

Weighted

Average

Exercise

Price

 

 

Aggregate

Intrinsic

Value

 

$0.95 - $8.75

 

 

14,697,448

 

 

$

2.40

 

 

 

7.5

 

 

$

4,595

 

 

 

8,404,207

 

 

$

3.23

 

 

$

2,893

 

 

The intrinsic value calculated as the excess of the market value as of September 30, 2021 over the exercise price of the options is $ 4,595. The market value per share as of September 30, 2021 was $1.03 as reported by the NASDAQ Capital Market.

Note 13. Income Taxes

A valuation allowance is recorded if it is more likely than not that a deferred tax asset will not be realized. The Company weighed available positive and negative evidence and concluded that a full valuation allowance should continue to be maintained on its net deferred tax assets.

The Company is required to evaluate uncertain tax positions taken or expected to be taken in the course of preparing the Company’s condensed consolidated financial statements to determine whether the tax positions are more likely than not of being sustained by the applicable tax authority. As of September 30, 2021, the Company’s uncertain tax positions remain unchanged. Due to the full valuation allowance, none of the gross unrecognized tax benefits, if recognized, would affect the effective tax rate at September 30, 2021.

The Company had no income tax related penalties or interest for periods presented in these condensed consolidated financial statements related to uncertain tax positions due to available net operating loss carryforwards, which would be recorded as tax expense should the Company accrue for such items.

 

                     

\

\\

 

 

19


Table of Contents

 

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The disclosures in this Quarterly Report are complementary to those made in our Annual Report on Form 10-K filed with the SEC on June 10, 2021 (the “2021 10-K”). You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing in this Quarterly Report as well as our audited financial statements, notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our 2021 Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of this report and of our 2021 Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. As used in this report, unless the context suggests otherwise, “we,” “us,” “our,” “the Company,” “TYME” or “Tyme Technologies” refer to Tyme Technologies, Inc. together with its subsidiary. All amounts in Management’s Discussion and Analysis of Financial Condition and Results of Operations are approximate.

Overview

 

TYME is an emerging biotechnology company developing CMBTsTM that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also maintaining patients’ quality of life through relatively low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic requirements to cause cancer cell death through oxidative stress and exposure to the body’s natural immune system.

 

The Company is currently focused on developing its novel compound, SM-88. The Company believes that early clinical results demonstrated by SM-88 in multiple advanced cancers, including pancreatic, prostate, sarcomas and breast, reinforce the potential of our emerging CMBT™ pipeline.

 

Strategic Review

 

In November 2020, TYME appointed Richie Cunningham as its new Chief Executive Officer. In January 2021, he commenced a comprehensive strategic review examining every facet of the Company, with the goals of assessing the Company’s existing opportunities, exploring untapped opportunities that may have been overlooked and maximizing the efficiency of our capital expenditures in an effort to unlock TYME’s full potential.

 

The strategic review was extensive and involved internal and external assessments by industry experts, KOLs and advisors with considerable experience in the various areas we sought to probe and explore.

 

The strategic review process resulted in several key takeaways including, but not limited to:

 

broad activity across 15 cancer types as seen in the First in Human study and Compassionate Use program and confirmation of strong IP portfolio provides us extra development opportunities, for which focus is critical;

 

 

the second-line Precision Promise trial is the priority in pancreatic cancer;

 

 

breast cancer is a priority indication for development as part of pipeline diversification beyond pancreatic cancer;

 

 

there is a need to refine our understanding of the MOA and identify biomarkers to enhance targeting of patient populations; and

 

 

the rapidly changing COVID-19 landscape requires a reevaluation of the market potential and development pathway for

 

TYME-19.

 

The Company’s current strategy, including ongoing studies and the Preclinical Pipeline Program, has been developed based on the takeaways from the strategic review.

 

Ongoing Studies

 

Precision Promise Trial- SM-88 with MPS as 2nd line therapy in metastatic pancreatic cancer

 

The Company has partnered with PanCAN to study SM-88 in an adaptive randomized Phase II/III trial with registration intent known as Precision PromiseSM. The objective of Precision Promise is to expedite the study and approval of promising therapies for pancreatic cancer by bringing multiple stakeholders together, including academic, industry and regulatory entities. In this trial which began in early 2020, SM-88 with MPS is being studied as monotherapy in a treatment arm for patients who have failed one prior line of chemotherapy.

 

20

 


Table of Contents

PanCAN is sponsoring Precision Promise and providing funding and other support. While TYME’s SM-88 is included in the trial, we do not oversee, conduct or control the trial. As of September 30, 2021, there were fifteen participating sites in the Precision Promise trial. PanCAN has approved adding 15 additional sites, with five new sites planned to open in early calendar year 2022 and an additional ten sites expected to open by the end of calendar year 2022.

 

Although we do not have details of the enrollment of the SM-88 cohort, the next likely event in the trial would be a determination of potential “graduation” from the Phase II portion of the trial to the Phase III confirmatory portion of the trial. We expect to learn if the trial advances to Phase III during the second half of calendar year 2022.

 

OASIS (Metastatic HR+/HER2- Breast Cancer After CDK4/6 Inhibitors)

 

This quarter, we entered into an agreement with Georgetown University to support a Phase II trial, OASIS, for SM-88 in patients with metastatic breast cancer who have HR+ and HER2- disease (“HR+/HER2-“). This represents approximately 73% of the annual breast cancer diagnoses in the US each year. The OASIS trial is an investigator-initiated prospective open-label Phase II trial evaluating the efficacy and safety of SM-88 with MPS for the treatment of metastatic HR+/ HER2- breast cancer after treatment with a CDK4/6 inhibitor. This trial is designed as a two-stage trial, enrolling up to 50 patients to receive SM-88 with MPS without additional therapies in patients who have failed or progressed after receiving two hormonal agents and a CDK4/6 inhibitor. The primary endpoint of this trial is ORR, with secondary endpoints including DOR, CBR at >24 weeks, PFS, and safety. The trial will be conducted at Georgetown University at a total of five sites within the Georgetown/MEDSTAR system located in Washington DC, Maryland, and New Jersey. Patient enrollment began this quarter with the first patient dosed in September. We plan to provide an update on the OASIS breast cancer study during the first half of calendar year 2023.

 

HoPES Phase II Trial in sarcoma

 

In early 2020, the open-label Phase 2 investigator sponsored trial of SM-88 therapy in sarcoma, HoPES, opened. This trial has two cohorts, each expecting to enroll 12 patients. The first is SM-88 with MPS as salvage treatment in patients with mixed rare sarcomas, the other is SM-88 with MPS as maintenance treatment for patients with metastatic Ewing’s sarcoma that had not progressed on prior therapy. The primary objectives are to measure ORR and PFS. Secondary objectives include DOR, OS, CBR using RECIST, and incidence of treatment-emergent AEs. The Joseph Ahmed Foundation is sponsoring this trial and the trial is being conducted by PI Dr. Chawla at the Sarcoma Oncology Center in Santa Monica, CA. We anticipate that the trial will complete enrollment by the end of the first half of calendar year 2022.

 

Preclinical Pipeline Programs

 

SM-88 MOA and Biomarker Research

 

The Company has begun a comprehensive translational preclinical program. We have engaged Evotec, a leading global research and development company to aid in the execution of these activities and are also incorporating several complementary academic collaborations into this multi-faceted program. The overall goal of these activities is to potentially identify actionable biomarkers of sensitivity and activity to SM-88 in various cancers, complementary combination drugs strategies for SM-88, and other cancer metabolism targets that could be targeted for treatment. Additionally, the Company intends to incorporate liquid and tumor biopsies to future clinical trials to contribute to the biomarker identification. We anticipate this engagement will have several stages, and that it is likely to last through this fiscal year and into future periods.

 

TYME 19 and TYME 18

 

TYME-18 is a CMBT compound under development that is delivered intratumorally. TYME-18 leverages a member of the bile acid family to create a potential treatment for inoperable tumors. Preliminary observations of the local administration of TYME-18, a combination of a proprietary surfactant system and natural sulfonic acid, suggested its potential as an important regulator of energy metabolism that may impede the ability of tumors to increase in size, which, in addition to its lytic functionality, could prove useful in difficult-to-treat cancers. In initial preclinical xenograft mouse studies, TYME-18 was able to completely resolve over 90 percent (11/12 mice) of established colorectal tumors within 12 days versus an average of over 600 percent growth in the control animals. 

 

TYME-19 is an oral synthetic member of the bile acid family. The Company also uses bile acids in its anticancer drug candidate, TYME-18. Because of its expertise in bile acids and their effects, the Company was able to identify TYME-19 as a well-characterized bile acid with potential antiviral properties. Bile acids have primarily been used for liver disease; however, like all steroids, they are messenger molecules that modulate a number of diverse critical cellular processes. Bile acids can modulate lipid and glucose metabolism and can remediate dysregulated protein folding, with potentially therapeutic effects on cardiovascular, neurologic,

 

21

 


Table of Contents

immune, and other metabolic systems. Some agents in this class have also previously shown antiviral properties. In in vitro preclinical testing, TYME-19 prevented COVID-19 viral replication at doses without meaningful cytotoxicity to the treated cells. Previous independent preclinical research has also shown select bile acids may have had broad antiviral activity.

 

Tumor Targeting Technology

 

TYME has developed a technology (“Tumor Targeting Technology”) by which the tyrosine isomer L metyrosine (L-α-methylparatyrosine) can be fused with a second therapeutic agent in a manner that creates a fusion compound that may allow targeted accumulation of the treatment by the cancer cells in a novel manner. This method of tumor targeting is predicated on the metabolic phenomenon in which cancer cells consume higher quantities of non-essential amino acids, including tyrosine, from their surrounding environment to support their growth because they cannot make enough of these amino acids. Tumor Targeting Technology is an investigational approach in the preclinical phase of development that is not approved in the U.S. for any disease indication and requires further preclinical development, which the Company plans to initiate this year.

 

Discontinuing Programs

 

TYME-88-PANC (Part 2) (third-line Metastatic Pancreatic Cancer)

 

In fiscal year 2020, we launched our pivotal study for SM-88 in the third-line treatment of pancreatic cancer through an amendment to our ongoing TYME-88-Panc trial (Part 2), with the first patient dosed in the third quarter of the fiscal year. As described previously, the COVID-19 pandemic significantly impacted enrollment of this trial such that it appeared it was likely to complete enrollment in a similar timeline to the second-line Precision Promise pancreatic cancer trial. There was also a higher than expected dropout rate of patients randomized to the chemotherapy control arm, which could have potentially impacted the interpretative and regulatory utility of the data. 

 

Following the strategic review discussed above, considering, in part, the timeline and regulatory utility for this trial compared to the parallel Precision Promise trial and concentration of investment in this specific cancer, management concluded that it would be best to focus on the second-line Precision Promise trial, which offers treatment options to patients earlier in their disease and includes tumor biopsy and biomarker analyses that align with the Company’s overall strategic focus on identifying targeted therapies.    

 

Therefore, the Company decided to stop enrollment and begin the process of closing down the trial. Patients currently on therapy will be allowed to continue treatment until progression or unacceptable toxicity. The closing of this trial is expected to require several months to complete. In the six months ended September 30, 2021, the Company expensed $843,000 of estimated closeout costs. The trial’s remaining ongoing expense to the Company is approximately $1.2 million, and is expected to be incurred over the next nine months.


COVID-19 Update

 

In March 2020, the World Health Organization categorized the novel coronavirus (COVID-19) as a pandemic, and the President of the United States declared the COVID-19 outbreak a national emergency. The COVID-19 pandemic, and actions taken by governments and others to reduce its spread, including travel restrictions, shutdowns of businesses deemed non-essential, and stay-at-home or similar orders, has negatively impacted the global economy, financial markets, and our industry and has disrupted day-to-day life and business operations. We continue to closely monitor the impact of COVID-19 on all aspects of our business, our clinical trials, and the safety of patients, including as vaccines become more widely available, as jurisdictions ease certain restrictions and as possible new outbreaks or virus variants emerge and jurisdictions evaluate new or renewed safety measures. We continue to work closely with our clinical trial sites during the pandemic, and are committed to working with them to assure appropriate access for patients who are seeking clinical trial options for these advanced cancers for which the patients have limited or no other treatment options.

 

We have also taken important steps to protect the health and welfare of our employees, consultants and board members, by continuing to provide a fully “work-from-home” option. The extent to which COVID-19 impacts our product candidates and business, including patients’ willingness to participate and remain in clinical trials, the timing of meeting enrollment expectations, the ability of our third-party partners to remain operational and our access to capital markets and financing sources, however, depends on numerous evolving factors that are highly uncertain and cannot be accurately predicted. Management continues to monitor the situation closely and intends to continue to adapt and implement process adjustments as needed.

 

Critical Accounting Policies and Significant Judgments and Estimates

This management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and

 

22

 


Table of Contents

liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses, warrant liability, and stock-based compensation. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes in our critical accounting policies and significant judgments and estimates as discussed in our 2021 10-K.

Derivative Warrant Liability

Certain freestanding common stock warrants that are related to the issuance of common stock are classified as liabilities and recorded at fair value due to characteristics that require liability accounting, primarily the obligation to issue registered shares of common stock upon notification of exercise or certain price protection provisions. Warrants of this type are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of other income (expense) in the consolidated statement of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant. The Company utilizes Level 3 fair value criteria to measure the fair value of the warrants.

As noted in Item 1. Note 8, Stockholders’ Equity, the Company classifies a warrant to purchase shares of its common stock as a liability on its condensed consolidated balance sheet if the warrant is a free-standing financial instrument that contains certain price protection features or requires issuance of registered common shares upon exercise which cause the warrants to be treated as derivatives. Each warrant of this type is initially recorded at fair value on date of grant using the Monte Carlo simulation model or the Black Scholes model, and is subsequently re-measured to fair value at each subsequent balance sheet date. Changes in fair value of the warrant are recognized as a component of other income (expense) in the condensed consolidated statement of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant.

Results of Operations

Three and Six Months Ended September 30, 2021 Compared to Three and Six Months Ended September 30, 2020

Net loss for the three months ended September 30, 2021 was $5,565,000 compared to $6,850,000 for the three months ended September 30, 2020 and the net loss for the six months ended September 30, 2021 was $11,494,000 compared to $15,676,000 for the six months ended September 30, 2020. The decrease in losses for the current three-month period is mostly due to lower research and development operating costs. The decrease in losses for the six month period is due to favorable variance of $3,843,000 in the change in fair value of the warrant liability offset by $2,229,000 prior years gain on the warrant exchange, as well as decreased operating costs. The decrease in operating costs for the current six month period of $2,513,000 related to decreased research and development costs of $1,743,000 and decreased general and administrative costs of $770,000.

Cash used in operating activities for the six-months ended September 30, 2021 was $10,280,000 compared to $12,764,000 for the six months ended September 30, 2020. See “Cash Flows section below for further details.

Revenues

During the three and six months ended September 30, 2021 and 2020, the Company did not realize any revenues from operations. We do not anticipate any revenues until such time as one of our product candidates has been approved for commercialization by appropriate regulatory authorities or we enter into certain types of collaboration or licensing arrangements, none of which is anticipated to occur in the near future.

Operating Costs and Expenses

For the three months ended September 30, 2021, operating costs and expenses totaled $5,928,000 compared to $7,321,000 for the three months ended September 30, 2020, a decrease of $1,393,000. Operating costs and expenses were comprised of the following:

 

Research and development expenses were $3,495,000 for the three months ended September 30, 2021, compared to $4,707,000 for the three months ended September 30, 2020, a decrease of $1,212,000. Nearly all research and development expenditures have been incurred in respect of our lead drug candidate SM-88 and its technology platform. Research and development activities primarily consist of the following:

 

o

Study and consulting expenses were $2,633,000 for the three months ended September 30, 2021, compared to $3,597,000 for the three months ended September 30, 2020. The decrease reflects lower ongoing trial costs due to the discontinued TYME-88-Panc Part 2 third-line Metastatic Pancreatic Cancer trial.

 

23

 


Table of Contents

 

o

Salary and salary-related expenses for research and development personnel were $727,000 for the three months ended September 30, 2021, compared to $765,000 for the three months ended September 30, 2020, a decrease of $38,000 primarily due to lower headcount for roles currently outsourced to consultants.

 

o

Included in research and development expense for the three months ended September 30, 2021 is $136,000 of stock-based compensation expense related to stock options granted to research and development personnel compared to $346,000 for the three months ended September 30, 2020, a decrease of $210,000 primarily attributable to fully vested grants and cancellation/forfeiture of options.

 

General and administrative expenses were $2,433,000 for the three months ended September 30, 2021, compared to $2,614,000 for the three months ended September 30, 2020, a decrease of $181,000. The general and administrative expenses for the respective periods include:

 

o

Other general and administrative expenses were $1,953,000 during the three months ended September 30, 2021, compared to $2,076,000 for the three months ended September 30, 2020, a decrease of $123,000, reflecting lower professional fees, and office rent expense.

 

o

Stock-based compensation expense related to stock options was $480,000 for the three months ended September 30, 2021 compared to $538,000 for the three months ended September 30, 2020, a decrease of $58,000, primarily attributable to fully vested grants and cancellation of options.

For the six months ended September 30, 2021, operating costs and expenses totaled $12,581,000 compared to $15,094,000 for the six months ended September 30, 2020, a decrease of $2,513,000. Operating costs and expenses were comprised of the following:

 

 

Research and development expenses were $7,680,000 for the six months ended September 30, 2021, compared to $9,423,000 for the six months ended September 30, 2020, a decrease of $1,743,000. Substantially all research and development expenditures have been incurred in respect of our lead drug candidate SM-88 and its technology platform. Research and development activities primarily consist of the following:

 

 

o

Study and consulting expenses were $6,098,000 for the six months ended September 30, 2021, compared to $7,149,000 for the six months ended September 30, 2020, a decrease of $1,051,000 between the comparable periods. The decrease is mainly attributable to lower ongoing trial costs due to the discontinued TYME-88-Panc Part 2 third-line Metastatic Pancreatic Cancer trial.

 

 

o

Salary and salary related expenses for research and development personnel were $1,273,000 for the six months ended September 30, 2021, compared to $1,420,000 for the six months ended September 30, 2020 a decrease of $147,000 primarily attributable to lower headcount for roles currently outsourced to consultants.

 

 

o

Included in research and development expense for the six months ended September 30, 2021 is $309,000 of stock based compensation expense related to stock options granted to research and development personnel compared to $853,000 for the six months ended September 30, 2020, a decrease of $544,000 primarily attributable to fully vested grants and cancellation/forfeiture of options.

 

 

General and administrative expenses were $4,901,000 for the six months ended September 30, 2021, compared to $5,671,000 for the six months ended September 30, 2020, a decrease of $770,000. The general and administrative expenses for the respective periods include:

 

 

o

Other general and administrative expenses were $3,950,000 during the six months ended September 30, 2021, compared to $4,571,000 for the six months ended September 30, 2020, a decrease of $621,000, reflecting lower professional fees and office rent expense.

 

 

o

Stock based compensation expense related to stock options was $951,000 for the six months ended September 30, 2021 compared to $1,100,000 for the six months ended September 30, 2020, a decrease of $149,000, primarily attributable to fully vested grants and cancellation of options.

 

 

24

 


Table of Contents

 

Other income (expense)

For the three months ended September 30, 2021, the Company had $344,000 non-cash income relating to the change in fair value of the warrant liability during the period, compared to $490,000 income for the three months ended September 30, 2020. For the six months ended September 30, 2021, the Company had $1,069,000 non-cash income relating to the change in fair value of the warrant liability during the period compared to $2,774,000 of non-cash expense for the six months ended September 30, 2020, resulting in a $3,843,000 variance between the periods. See Item 1, Note 8 for details regarding changes in the fair value of the warrant liability.

For the six months ended September 30, 2020, the Company had a non-cash gain on warrant exchanges of $2,229,000 pursuant to the Share Exchange Agreements and the Warrant Exchange Agreement. See Item 1, Note 8 for additional details.

For the three and six months ended September 30, 2021 the Company had investment income and interest income on cash accounts of $38,000 and $59,000 compared to $7,000 and $17,000 for the three and six months ended September 30, 2020. For the three and six months ended September 30, 2021, the Company had interest expense primarily related to the amortization of the severance payable discount of $19,000 and $41,000 compared to $26,000 and $55,000 for the three and six months ended September 30, 2020.

Adjusted Net Loss and Adjusted Net Loss per Share

 

After adjusting for change in fair value of warrant liability, amortization of employees, directors and consultants stock options and gain on warrant exchange, adjusted net loss for the three months ended September 30, 2021 was $5,293,000 or $0.03 per share compared to $6,457,000 or $0.04 per share for the three months ended September 30, 2020. Adjusted net loss for the six-month period ended September 30, 2021 was $11,303,000 or $0.07 per share compared to $13,178,000 or $0.10 per share for the same period in the prior year. Adjusted net loss and adjusted net loss per share are non-GAAP measures. See “Use of Non-GAAP Measures” below for a reconciliation to the comparable GAAP measures.

 

Use of Non-GAAP Measures

 

Adjusted net loss and adjusted net loss per share as presented in this report are non-GAAP measures. The adjustments relate to the change in fair value of warrant liabilities, amortization of employees, directors and consultants stock based compensation and gain on warrant exchange. These financial measures are presented on a basis other than in accordance with U.S. generally accepted accounting principles ("Non-GAAP Measures"). In the reconciliation tables that follow, we present adjusted net loss and adjusted net loss per share, reconciled to their comparable GAAP measures, net loss and net loss per share. These items are adjusted because they are not operational or because they are significant non-cash charges and management believes these adjustments are meaningful to understanding the Company's performance during the periods presented. These Non-GAAP Measures should be considered a supplement to, not a substitute for, or superior to, the corresponding financial measures calculated in accordance with GAAP. Our definitions of adjusted net loss and adjusted loss per share may not be comparable to similar measures reported by other companies.

 

25

 


Table of Contents

 

Reconciliation of Net Loss to Adjusted Net Loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

September 30,

 

 

Six Months Ended                   September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Net loss (GAAP)

 

$

(5,565,000

)

 

$

(6,851,000

)

 

$

(11,494,000

)

 

$

(15,676,000

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of warrant liability

 

 

(344,000

)

 

 

(490,000

)

 

 

(1,069,000

)

 

 

2,774,000

 

Amortization of employees, directors and consultants stock options

 

 

616,000

 

 

 

884,000

 

 

 

1,260,000

 

 

 

1,953,000

 

Gain on warrant exchange

 

 

 

 

 

 

 

 

 

 

 

(2,229,000

)

Adjusted net loss (non-GAAP)

 

$

(5,293,000

)

 

$

(6,457,000

)

 

$

(11,303,000

)

 

$

(13,178,000

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of Net Loss Per Share to Adjusted Net Loss Per Share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

September 30,

 

 

Six Months Ended                   September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Net loss per share (GAAP)

 

$

(0.03

)

 

$

(0.05

)

 

$

(0.07

)

 

$

(0.12

)

Adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of warrant liability

 

*

 

 

*

 

 

 

(0.01

)

 

 

0.02

 

Amortization of employees, directors and consultants stock options

 

*

 

 

 

0.01

 

 

 

0.01

 

 

 

0.02

 

Gain on warrant exchange

 

 

 

 

 

 

 

 

 

 

 

(0.02

)

Adjusted net loss per share (non-GAAP)

 

$

(0.03

)

 

$

(0.04

)

 

$

(0.07

)

 

$

(0.10

)

* The effect of the change was negligible to the adjusted net loss per share.

 

 

The Non-GAAP Measures for the three and six months ended September 30, 2021 and 2020 provide management with additional insight into the Company’s results of operations from period to period by excluding certain non-operational and non-cash charges, and are calculated using the following adjustments to net loss:

 

 

a)

The May 2020 Warrant issued as part of the warrant exchange as described under the subheading “Historical Financings” below was measured at fair value using a Black-Scholes model which takes into account, as of the valuation date, factors including the current exercise price, the remaining contractual term of the warrant, the current price of the underlying stock, its expected volatility and the risk-free interest rate for the term of the warrant.

 

The warrant liability is revalued at each reporting period or upon exercise. Changes in fair value are recognized in the consolidated statements of operations and are excluded from adjusted net loss and adjusted net loss per share.

 

 

b)

The Company uses the Black-Scholes option pricing model to determine fair value of stock options granted. For employees and non-employees, the compensation expense is amortized over the requisite service period which approximates the vesting period. The expense is excluded from adjusted net loss and adjusted net loss per share.

 

 

c)

Gain on warrant exchange resulted from the difference in fair value of the warrants issued as part of the equity offering on April 2, 2019 before their exchange (as described under the subheading “Historical Financings” below) and the fair value of the common stock exchange shares and the May 2020 warrant granted pursuant to the Share Exchange Agreements and the Warrant Exchange Agreement, respectively.

 

Adjusted basic net loss per share is computed by dividing adjusted net loss by the weighted average number of shares of Company common stock outstanding for the period, and adjusted diluted loss per share is computed by also including common stock equivalents outstanding for the period. During the periods presented, the calculation excludes any potential dilutive common shares and any equivalents as they would have been anti-dilutive as the Company incurred losses for the periods then ended.

 

26

 


Table of Contents

Liquidity and Capital Resources

Liquidity and Capital Requirements Outlook


On February 8, 2021, the Company closed on a registered direct offering of 40,000,000 shares of its common stock, par value $0.0001 per share, at a purchase price of $2.50 per share. The gross proceeds of the offering were $100 million, prior to deducting placement agent’s fees and other offering expenses payable by TYME, which were approximately $6.2 million.

 

The Company intends to continue to use the net proceeds of this offering for the development of our clinical and preclinical assets and for general corporate purposes, capital expenditures, working capital and general and administrative expenses. We may also use a portion of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions. In addition, we may also use the proceeds, and may require additional capital, to engage in potential partnerships or collaborations. The Company’s most significant funding needs are in connection with (i) participating in Precision Promise, an adaptive randomized Phase II/III trial with registration intent, which examines our lead compound SM-88 for patients with second-line pancreatic cancer, and closing out our Part 2 of TYME-88 pivotal trial, (ii) participating in the investigator-initiated HoPES clinical trial of SM-88 in sarcoma, (iii) participating in OASIS, our recently announced investigator-initiated prospective open-label Phase II trial, evaluating the efficacy and safety of SM-88 with MPS for the treatment of metastatic HR+, HER2- breast cancer after treatment, and (iv) conducting preclinical biomarker and MOA research of our lead clinical program SM-88 to potentially identify actionable biomarkers of sensitivity and activity to SM-88 in various cancers, identifying potential complementary combination drugs strategies for SM-88, and potentially identify other cancer metabolism targets that could be targeted for treatment, and (v) conducting preclinical and clinical studies in connection with TYME-19, and (vi) conducting preclinical studies related to our Tumor Targeting Technology, and (vii) conducting additional or related studies of other potential drug candidates, including TYME-18. The greater scale of these trials is expected to lead to increased costs, including providing SM-88 for patient use. If we determine to move beyond the preclinical stage for any of our preclinical product candidates or if we pursue studies in other cancer types, our liquidity requirements will be increased.

 

Primarily as a result of its active clinical trials, including timing of enrollment, as well as other business developments, the Company currently anticipates that its quarterly cash operating expense will average approximately $6.0 to $8.0 million during fiscal year 2022. Management expects that the Company’s net cash usage or net “cash burn” will be less than its operating costs.

 

As of September 30, 2021, the Company had cash on hand of approximately $29.2 million and a working capital of approximately $72.6 million. During the three months ended June 30, 2021, the Company established an investment policy and invested approximately $74.1 million in a portfolio of highly liquid investments and marketable securities. As of September 30, 2021, the Company had marketable securities of $66.7 million and accrued interest of $0.7 million classified in other current assets. The primary objectives of the Company’s policy are to preserve capital and diversify risk, while maintaining sufficient liquidity to meet cash flow needs.

 

Management has concluded that substantial doubt does not exist regarding the Company’s ability to satisfy its obligations as they come due during the twelve-month period following the issuance of these financial statements. This conclusion is based on the Company’s assessment of qualitative and quantitative conditions and events, considered in aggregate as of the date of issuance of these financial statements that are known and reasonably knowable. Among other relevant conditions and events, including the ongoing COVID-19 pandemic and related government and economic responses, the Company has considered its operational plans, liquidity sources, obligations due or expected, funds necessary to maintain the Company’s operations, and potential adverse conditions or events as of the issuance date of these financial statements.

 

The Company has historically funded its operations primarily through equity offerings of its common stock. As a clinical-stage entity, without product revenues and ongoing needs to fund our clinical development activities and general operations, we regularly evaluate opportunities to raise capital and obtain necessary, as well as opportunistic financing. To meet our short and long-term liquidity needs, we currently expect to use existing cash balances, marketable securities and a variety of other means, including potential issuances of debt or equity securities in public or private financings, option exercises, and partnerships and/or collaborations. The demand for the equity and debt of biopharmaceutical and biotechnology companies like ours is dependent upon many factors, including the general state of the financial markets. During times of extreme market volatility, capital may not be available on favorable terms, if at all. Our inability to obtain such additional capital could materially and adversely affect our business operations.

 

While we will continue to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and our negotiating position in capital generating efforts may worsen as existing resources are used.

 

 

27

 


Table of Contents

 

Additional equity financing, which we expect to raise, may be dilutive to our stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict our ability to operate as a business; and our stock price may not reach levels necessary to induce option exercises. If we are unable to raise the funds necessary to meet our long-term liquidity needs, we may have to delay or discontinue the development of certain or all of our drug candidates or raise funds on terms that we currently consider unfavorable.

 

From time to time, we may also restructure our outstanding securities or seek to repurchase or redeem them if we believe doing so would provide us with additional flexibility to raise capital or is otherwise in the best interests of the Company.

 

Historical Financings

 

On January 7, 2020, the Company and Eagle Pharmaceuticals, Inc. (“Eagle”) entered into an SPA (the “Eagle SPA”), pursuant to which the Company issued and sold to Eagle 10,000,000 shares of common stock, at a price of $2.00 per share. The Eagle SPA provides that Eagle will, subject to certain conditions, make an additional payment of $20 million upon the occurrence of a milestone event, which is defined as the earlier of (i) achievement of the primary endpoint of OS in the TYME-88-Panc pivotal trial; (ii) achievement of the primary endpoint of OS in the PanCAN Precision PromiseSM SM-88 registration arm; or (iii) FDA approval of SM-88 in any cancer indication. This payment would be split into a $10 million milestone cash payment and a $10 million investment in TYME at a 15% premium to the then prevailing market price. Eagle’s shares will be restricted from sale until the earlier of three months following the milestone event or the three-year anniversary of the agreement.

 

On October 18, 2019, the Company entered into an Open Market Sale AgreementSM , which was amended on August 12, 2020 (the “Sale Agreement”) with Jefferies LLC (“Jefferies”), pursuant to which the Company may, from time to time, sell shares of Common Stock, having an aggregate offering price of up to $30.0 million through Jefferies, as the Company’s sales agent (the “Jefferies ATM”). As indicated in the amendment, the shares will be offered and sold by the Company pursuant to its currently effective Registration Statement on Form S-3, as amended (Reg. No. 333-245033). Any sales of Common Stock pursuant to the Sales Agreement will be made by methods deemed to be an “at-the-market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. Jefferies will use commercially reasonable efforts to sell the shares from time to time, based on the instructions of the Company. The Company will pay Jefferies a commission rate of three percent (3%) of the gross proceeds from the sales of shares of Common Stock sold pursuant to the Sale Agreement. Under the Sale Agreement, the Company is not required to use the full available amount authorized and it may, by giving notice as specified in the Sale Agreement, terminate the Sale Agreement at any time. During the six months ended September 30, 2021, the Company did not raise any proceeds under the Jefferies ATM. As of September 30, 2021, there remained approximately $22.2 million of availability in the Jefferies ATM.

 

In May 20, 2020, the Company entered into exchange agreements (the “Share Exchange Agreements”) with the Holders of warrants that were issued in April 2019 (the “April 2019 Warrants”). Pursuant to the Share Exchange Agreements with Holders of the April 2019 Warrants to purchase 5,833,333 shares of Common Stock in the aggregate, the Company issued an aggregate of 2,406,250 shares of Common stock (the “Exchange Shares”) in exchange for such April 2019 Warrants. Concurrently therewith, each such Holder executed and delivered to the Company a leak-out agreement (a “Share Leak-Out Agreement”) that contained trading restrictions with respect to the Exchange Shares, which (i) for the first 90 days, prohibit any sales of Exchange Shares, (ii) for the subsequent 90 days, limit sales of Exchange Shares on any day to 2.5% of that day’s trading volume of Common Stock, and (iii) prohibit new short positions or short sales on Common Stock for the combined 180 day period.

 

The Company also entered into an exchange agreement (the “Warrant Exchange Agreement”) with another Holder of April 2019 Warrants to purchase 2,166,667 shares of Common Stock in the aggregate. Pursuant to the Warrant Exchange Agreement, the Company issued such Holder a new warrant (the “May 2020 Warrant”) to purchase the same number of shares of Common Stock. The May 2020 Warrant has the same expiration date, April 2, 2024, as the April 2019 Warrants, but has an exercise price of $1.80 and does not include certain price protection, anti-dilution provisions or other restrictions on Company action from the 2019 April Warrants. Concurrently therewith, such Holder executed and delivered to the Company a leak-out agreement that contained trading restrictions on sales of Common Stock issued upon exercise of the May 2020 Warrant that are substantially similar to the restrictions on Exchange Shares in the Share Leak-Out Agreement, provided that the leak-out restrictions will only apply to the first 893,750 shares of Common Stock issued pursuant to the May 2020 Warrant.

 

After such exchanges, the April 2019 Warrants no longer remained outstanding.

 

 

28

 


Table of Contents

 

Cash Flows

Net cash used in or provided by operating, investing and financing activities from continuing operations were as follows:

 

 

 

Six Months Ended September 30,

 

 

 

2021

 

 

2020

 

Net cash (used in) provided by operating activities

 

$

(10,280,000

)

 

$

(12,764,000

)

Net cash (used in) provided by investing activities

 

 

(68,027,000

)

 

 

 

Net cash (used in) provided by financing activities

 

 

6,000

 

 

 

5,463,000

 

Operating Activities

Our cash used in operating activities in the six months ended September 30, 2021 totaled $10.3 million, which is the sum of (i) our net loss of $11.5 million, adjusted for non-cash items of $1.3 million expense amortization of stock-based compensation and $0.7 million net amortization expense of premiums and discounts on marketable securities, offset by $1.1 million income related to change in fair value of warrant liability and (ii) changes in operating assets and liabilities of $0.3 million.

Our cash used in operating activities in the six months ended September 30, 2020 totaled $12.8 million, which is the sum of (i) our net loss of $15.7 million, adjusted for non-cash expenses of $2.8 million related to change in fair value of warrant liability and $2.0 million expense amortization of stock-based compensation, partially offset by $2.2 million non-cash gain on warrant exchange and (ii) changes in operating assets and liabilities of $0.3 million.

 

Investing Activities

During the six months ended September 30, 2021, our investing activities consisted of the purchase of $74.5 million of marketable securities and the receipt of approximately $6.5 million of proceeds from maturities of marketable securities.

Financing Activities

 

During the six months ended September 30, 2021, our financing activities consisted of the receipt of $6,000 in proceeds from the exercise of stock options.

Seasonality

The Company does not believe that its operations are seasonal in nature.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.

 

29

 


Table of Contents

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.  

Not required for smaller reporting companies.

Item 4.

Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Under the supervision of and with the participation of management, including our principal executive officer and acting principal financial officer, we evaluated the effectiveness of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities and Exchange Act of 1934, as amended, as of September 30, 2021. Based on such evaluation, our principal executive officer and acting principal financial officer concluded that our disclosure controls and procedures were effective.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

30

 


Table of Contents

PART II – OTHER INFORMATION

Item 1.

We are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on us, our business, operating results or financial condition.

Item 1A.

Risk Factors.

Our Annual Report on Form 10-K for the year ended March 31, 2021 includes a detailed discussion of our risk factors. At the time of this filing, there have been no material changes to the risk factors that were included in the Form 10-K.

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3.

Defaults Upon Senior Securities.

None.

Item 4.

Mine Safety Disclosures.

Not applicable.

 

Item 5.    Other Information.

On November 4, 2021, Paul Sturman notified the Board of Directors of the Company (the “Board”) that he was resigning from our Board, effective immediately. Mr. Sturman’s decision to retire is not the result of any disagreement with the Company. The written correspondence provided by Mr. Sturman is attached hereto as Exhibit 99.1.

  

    

 

 

31

 


Table of Contents

 

Item 6.

Exhibits.

 

Exhibit

  

 

Number

  

Description

 

 

    3.1

 

Amended and Restated Certificate of Incorporation of Tyme Technologies, Inc. (Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K, filed with the SEC on September 19, 2014.)

 

 

 

    3.2

 

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Tyme Technologies, Inc., effective April 2, 2018. (Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K, filed with the SEC on April 2, 2018.)

 

    3.3

 

Certificate of Designation of Series A Convertible Stock, dated January 7, 2020. (Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K, filed with the SEC on January 8, 2020.)

 

    3.4

 

Amended and Restated By-Laws of Tyme Technologies, Inc., effective August 24, 2021. (Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K, filed with the SEC on August 26, 2021.)

 

    3.5

 

Amended and Restated 2016 Stock Option Plan for Non-Employee Directors of the Registrant, incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K, filed with the Commission on August 26, 2021.

 

  31.1 *

  

Rule 13(a)-14(a)/15(d)-14(a) Certification of Principal Executive Officer.

 

 

  31.2 *

  

Rule 13(a)-14(a)/15(d)-14(a) Certification of Principal Financial Officer.

 

 

  32.1 **

  

Section 1350 Certification of Principal Executive Officer and Principal Financial Officer.

 

 

  99.1 *

  

Resignation Letter of Paul Sturman, dated November 4, 2021.

 

 

101.INS *

  

Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

 

101.SCH *

  

Inline XBRL Taxonomy Schema Document.

 

 

101.CAL *

  

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

 

 

101.DEF *

  

Inline XBRL Taxonomy Extension Definition Linkbase Document.

 

 

101.LAB *

  

Inline XBRL Taxonomy Extension Label Linkbase Document.

 

 

101.PRE *

  

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

 

 

104

  

Cover Page Interactive Data File, formatted in Inline XBRL (contained in Exhibit 101.INS)

 

* 

Filed herewith.

**

Furnished herewith.

 

32

 


Table of Contents

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 8, 2021

 

TYME TECHNOLOGIES, INC.

 

 

By:

 

/s/ Richard Cunningham

 

 

Richard Cunningham

 

 

Chief Executive Officer

(Principal Executive Officer)

 

By:

 

/s/ Frank Porfido

 

 

Frank Porfido

 

 

Chief Financial Officer

(Principal Financial Officer)

 

By:

 

/s/ Barbara Galaini

 

 

Barbara Galaini

 

 

Corporate Controller

(Principal Accounting Officer)

 

 

 

33